Larimar Therapeutics (LRMR) Cash from Investing Activities Growth (3y) (2016 - 2024)
Larimar Therapeutics (LRMR) Cash from Investing Activities Growth (3y) (2016 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 43.55% |
| Sep 30, 2024 | 81.87% |
| Jun 30, 2024 | -74.39% |
| Mar 31, 2024 | -146.73% |
| Dec 31, 2023 | 51.85% |
| Sep 30, 2023 | -1,697.09% |
| Jun 30, 2023 | -30.79% |
| Mar 31, 2023 | 394.03% |
| Dec 31, 2022 | -914.68% |
| Dec 31, 2021 | -23.09% |
| Sep 30, 2021 | 47.69% |
| Jun 30, 2021 | 32.06% |
| Mar 31, 2021 | -33.63% |
| Dec 31, 2020 | -56.80% |
| Sep 30, 2020 | -26.59% |
| Jun 30, 2020 | 43.60% |
| Mar 31, 2020 | -27.84% |
| Dec 31, 2019 | -26.05% |
| Jun 30, 2019 | -30.45% |
| Mar 31, 2019 | -61.62% |